Not available
Quote | Apellis Pharmaceuticals Inc. (NASDAQ:APLS)
Last: | $35.88 |
---|---|
Change Percent: | 1.33% |
Open: | $35.75 |
Close: | $35.41 |
High: | $35.98 |
Low: | $35.0981 |
Volume: | 136,174 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Apellis Pharmaceuticals Inc. (NASDAQ:APLS)
2024-06-28 10:19:27 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks Apellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transc...
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of i...
Message Board Posts | Apellis Pharmaceuticals Inc. (NASDAQ:APLS)
Subject | By | Source | When |
---|---|---|---|
news out | IPO$ | investorshub | 05/09/2023 2:24:06 AM |
The gaining last trade up | IPO$ | investorshub | 05/07/2023 6:10:22 PM |
Price now last trade up | IPO$ | investorshub | 05/04/2023 2:09:52 PM |
$APLS are we finally gonna see some action | Pedro2004 | investorshub | 05/01/2023 11:51:02 PM |
where is the squeeze? | wantprofits | investorshub | 04/29/2023 7:51:08 AM |
News, Short Squeeze, Breakout and More Instantly...
Apellis Pharmaceuticals Inc. Company Name:
APLS Stock Symbol:
NASDAQ Market:
Apellis Pharmaceuticals Inc. Website:
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of i...
2024-06-19 19:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announ...